AbbVie Inc. Treasury Stock, Shares, Acquired
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- AbbVie Inc. treasury stock, shares, acquired for the quarter ending 2017-12-31 was 5.20M shares.
- AbbVie Inc. treasury stock, shares, acquired for the quarter ending 2017-09-30 was 0.00 shares.
- AbbVie Inc. treasury stock, shares, acquired for the quarter ending 2017-06-30 was 0.00 shares.
- AbbVie Inc. treasury stock, shares, acquired for the quarter ending 2017-03-31 was 7.80M shares.
- AbbVie Inc. treasury stock, shares, acquired for fiscal 2017 was 13.00M shares, a 61.76% decline from fiscal 2016.
- AbbVie Inc. treasury stock, shares, acquired for fiscal 2016 was 34.00M shares, a 26.09% decline from fiscal 2015.
- AbbVie Inc. treasury stock, shares, acquired for fiscal 2015 was 46.00M shares, a 411.11% increase from fiscal 2014.
- AbbVie Inc. treasury stock, shares, acquired for fiscal 2014 was 9.00M shares, a 125.00% increase from fiscal 2013.
| Period end | Treasury Stock, Shares, Acquired 3 month | Treasury Stock, Shares, Acquired 12 month |
|---|---|---|
| 2017-12-31 | 5.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | 13.00M shares 10-K · filed 2018-02-16 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | |
| 2017-03-31 | 7.80M shares 10-Q · filed 2017-05-05 | |
| 2016-12-31 | 34.00M shares 10-K · filed 2018-02-16 | |
| 2015-12-31 | 25.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | 46.00M shares 10-K · filed 2018-02-16 |
| 2015-09-30 | 17.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | 25.00M shares derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | 8.00M shares derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | 4.00M shares 10-Q · filed 2016-05-06 | 8.00M shares derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | 4.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | 9.00M shares 10-K · filed 2017-02-17 |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | 8.50M shares derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 8.50M shares derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | 5.00M shares 10-Q · filed 2015-05-08 | 9.00M shares derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | 3.50M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | 4.00M shares 10-K · filed 2016-02-19 |
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2013-06-30 | 500.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | |
| 2013-03-31 | 0.00 shares 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |